PharmaPhoto: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PharmaPhoto
Largest movements
- Receivables within one year -€14,212
down €14,212 (-37.4%), from €38,034 to €23,822
of which Trade receivables: -€9,340
- Receivables after one year +€10,000
up €10,000 (+40.0%), from €25,000 to €35,000
- Deferred charges and accrued income -€7,150
no longer reported in 2025 (was €7,150)
- Cash +€1,300
up €1,300 (+19.8%), from €6,577 to €7,877
mainly Receivables within one year (+€14,212) and Net result for the year (+€9,556)
- Trade debts -€17,891
down €17,891 (-39.0%), from €45,909 to €28,019
- Profit (loss) carried forward +€9,556
up €9,556 (+80.0%), from -€11,948 to -€2,391
- Tax, wage and social debts -€2,613
no longer reported in 2025 (was €2,613)
- Accrued charges and deferred income +€886
up €886 (+243.4%), from €364 to €1,250
- Gross operating margin +€29,716
up €29,716, from -€19,859 to €9,856
- Write-downs -€3,750
no longer reported in 2025 (was €3,750)
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €76,761 | €66,699 | -€10,062 | -13.1% |
| Current assets | 29/58 | €76,761 | €66,699 | -€10,062 | -13.1% |
| Amounts receivable after more than one year | 29 | €25,000 | €35,000 | +€10,000 | +40.0% |
| Other amounts receivable | 291 | €25,000 | €35,000 | +€10,000 | +40.0% |
| Amounts receivable within one year | 40/41 | €38,034 | €23,822 | -€14,212 | -37.4% |
| Trade receivables | 40 | €31,632 | €22,292 | -€9,340 | -29.5% |
| Other amounts receivable | 41 | €6,402 | €1,530 | -€4,872 | -76.1% |
| Cash at bank and in hand | 54/58 | €6,577 | €7,877 | +€1,300 | +19.8% |
| Deferred charges and accrued income | 490/1 | €7,150 | - | -€7,150 | |
| Total equity and liabilities | 10/49 | €76,761 | €66,699 | -€10,062 | -13.1% |
| Equity | 10/15 | -€1,948 | €7,609 | +€9,556 | |
| Contributions | 10/11 | €10,000 | €10,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€11,948 | -€2,391 | +€9,556 | +80.0% |
| Amounts payable | 17/49 | €78,709 | €59,091 | -€19,618 | -24.9% |
| Amounts payable after more than one year | 17 | €29,822 | €29,822 | = | 0.0% |
| Other amounts payable | 178/9 | €29,822 | €29,822 | = | 0.0% |
| Amounts payable within one year | 42/48 | €48,523 | €28,019 | -€20,504 | -42.3% |
| Trade debts | 44 | €45,909 | €28,019 | -€17,891 | -39.0% |
| Suppliers | 440/4 | €45,909 | €28,019 | -€17,891 | -39.0% |
| Taxes, remuneration and social security | 45 | €2,613 | - | -€2,613 | |
| Taxes | 450/3 | €2,613 | - | -€2,613 | |
| Accrued charges and deferred income | 492/3 | €364 | €1,250 | +€886 | +243.4% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | €3,750 | - | -€3,750 | |
| Other operating charges | 640/8 | - | €124 | +€124 | |
| Gross operating margin | 9900 | -€19,859 | €9,856 | +€29,716 | |
| Operating profit (loss) | 9901 | -€23,609 | €9,732 | +€33,342 | |
| Financial charges | 65/66B | €30 | €176 | +€146 | +486.7% |
| Recurring financial charges | 65 | €30 | €176 | +€146 | +486.7% |
| Profit (loss) for the period before taxes | 9903 | -€23,639 | €9,556 | +€33,196 | |
| Profit (loss) for the period | 9904 | -€23,639 | €9,556 | +€33,196 | |
| Profit (loss) for the period to be appropriated | 9905 | -€23,639 | €9,556 | +€33,196 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 9 October 2026 via checked.be.